Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Rating of “Hold” from Analysts

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have earned an average rating of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $4.75.

Several research firms recently weighed in on IPSC. Wall Street Zen cut Century Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 27th. Mizuho initiated coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 target price for the company. Zacks Research cut shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 12th. HC Wainwright upped their price target on shares of Century Therapeutics from $2.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research report on Monday, April 6th.

Century Therapeutics Stock Performance

Century Therapeutics stock remained flat at $2.43 during trading hours on Friday. 839,792 shares of the company’s stock traded hands, compared to its average volume of 1,979,832. The stock has a market capitalization of $438.25 million, a price-to-earnings ratio of -2.13 and a beta of 1.55. Century Therapeutics has a 52-week low of $0.44 and a 52-week high of $3.04. The business’s 50 day moving average is $2.28 and its 200-day moving average is $2.07.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. Equities analysts expect that Century Therapeutics will post -0.43 earnings per share for the current year.

Institutional Investors Weigh In On Century Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in IPSC. Prudential Financial Inc. bought a new stake in shares of Century Therapeutics in the second quarter valued at approximately $25,000. Bank of New York Mellon Corp acquired a new position in Century Therapeutics in the first quarter valued at about $29,000. Qube Research & Technologies Ltd bought a new stake in Century Therapeutics during the second quarter worth about $38,000. Quadrant Private Wealth Management LLC grew its stake in Century Therapeutics by 31.0% during the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock worth $45,000 after buying an additional 4,736 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Century Therapeutics during the second quarter worth about $51,000. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.